Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Public ClinicalTrials.gov record NCT01522820. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I trial studies the side effects and best schedule of vaccine therapy with or without sirolimus in treating patients with cancer-testis antigen (NY-ESO-1) expressing solid tumors. Biological therapies, such as sirolimus, may stimulate the immune system in different ways and stop tumor cells from growing. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells that express NY-ESO-1. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells. It is not yet known whether vaccine therapy works better when given with or without sirolimus in treating solid tumors.
Study identification
- NCT ID
- NCT01522820
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 18 participants
Conditions and interventions
Conditions
- Anaplastic Astrocytoma
- Anaplastic Oligoastrocytoma
- Anaplastic Oligodendroglioma
- Estrogen Receptor Negative
- Estrogen Receptor Positive
- Glioblastoma
- Hormone-Resistant Prostate Cancer
- Metastatic Prostate Carcinoma
- Metastatic Renal Cell Cancer
- Recurrent Adult Brain Neoplasm
- Recurrent Bladder Carcinoma
- Recurrent Breast Carcinoma
- Recurrent Colorectal Carcinoma
- Recurrent Esophageal Carcinoma
- Recurrent Gastric Carcinoma
- Recurrent Hepatocellular Carcinoma
- Recurrent Lung Carcinoma
- Recurrent Melanoma
- Recurrent Ovarian Carcinoma
- Recurrent Prostate Carcinoma
- Recurrent Renal Cell Carcinoma
- Recurrent Uterine Corpus Carcinoma
- Resectable Hepatocellular Carcinoma
- Sarcoma
- Stage IA Breast Cancer
- Stage IA Ovarian Cancer
- Stage IA Uterine Corpus Cancer
- Stage IB Breast Cancer
- Stage IB Ovarian Cancer
- Stage IB Uterine Corpus Cancer
- Stage IC Ovarian Cancer
- Stage II Uterine Corpus Cancer
- Stage IIA Breast Cancer
- Stage IIA Lung Carcinoma
- Stage IIA Ovarian Cancer
- Stage IIB Breast Cancer
- Stage IIB Esophageal Cancer
- Stage IIB Lung Carcinoma
- Stage IIB Ovarian Cancer
- Stage IIB Skin Melanoma
- Stage IIC Ovarian Cancer
- Stage IIC Skin Melanoma
- Stage IIIA Breast Cancer
- Stage IIIA Esophageal Cancer
- Stage IIIA Lung Carcinoma
- Stage IIIA Ovarian Cancer
- Stage IIIA Skin Melanoma
- Stage IIIA Uterine Corpus Cancer
- Stage IIIB Breast Cancer
- Stage IIIB Esophageal Cancer
- Stage IIIB Ovarian Cancer
- Stage IIIB Skin Melanoma
- Stage IIIB Uterine Corpus Cancer
- Stage IIIC Breast Cancer
- Stage IIIC Esophageal Cancer
- Stage IIIC Ovarian Cancer
- Stage IIIC Skin Melanoma
- Stage IIIC Uterine Corpus Cancer
- Stage IV Bladder Urothelial Carcinoma
- Stage IV Esophageal Cancer
- Stage IV Ovarian Cancer
- Stage IV Prostate Cancer
- Stage IV Skin Melanoma
- Stage IVA Uterine Corpus Cancer
- Stage IVB Uterine Corpus Cancer
Interventions
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401 Biological
- Laboratory Biomarker Analysis Other
- Pharmacological Study Other
- Sirolimus Drug
Biological · Other · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 29, 2012
- Primary completion
- Jun 30, 2016
- Completion
- Jun 30, 2016
- Last update posted
- Oct 3, 2016
2012 – 2016
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01522820, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 3, 2016 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01522820 live on ClinicalTrials.gov.